- NLS Pharmaceutics (NASDAQ:NLSP) has been awarded Canadian Patent No. 3016852 to provide intellectual property protection for oral formulations containing immediate-release and sustained-release layers of mazindol for use in treating attention deficit disorders, related alertness of vigilance or excessive daytime sleepiness (EDS), narcolepsy, or idiopathic hypersomnia.
- "Most patients with narcolepsy remain unsatisfied with current treatment options, and we believe that Quilience has potential to fill a major need in the market given mazindol's long history of safety and evidence of effectiveness in treating the symptoms of narcolepsy," Alex Zwyer CEO said.
- Shares up nearly 4% premarket.